Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | DBH | P09172 | 1/20 | 0.30 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26131698 | 0.77 | — | — | |
| SCHEMBL3694620 | 0.75 | PTGS2 (0.37) | TDP1 | |
| SCHEMBL6189654 | 0.69 | — | — | |
| SCHEMBL17514799 | 0.69 | ALDH1A1 (0.39) | — | |
| SCHEMBL13087966 | 0.69 | PDGFRB (0.37) | PDGFRBPDGFRADBHTUBB1TDP1 | |
| SCHEMBL2001106 | 0.69 | HDAC1 (0.31) | — | |
| SCHEMBL17110552 | 0.68 | TUBB1 (0.32) | TUBB1ACHE | |
| SCHEMBL17110516 | 0.68 | TUBB1 (0.32) | TUBB1 | |
| SCHEMBL6051936 | 0.68 | TUBB1 (0.31) | PDGFRBPDGFRATUBB1 | |
| SCHEMBL22883762 | 0.67 | TDP1 (0.36) | PDGFRBPDGFRADBHTUBB1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | claimed |
| US-RE39680-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | claimed |
| US-7217676-B2 | Hydrophobization and silica for supported catalyst | EXXON MOBIL CHEMICAL PATENTS INC. (US) | 2007-05-15 | — | — | US | claimed |
| US-20060264320-A1 | Hydrophobization and silica for supported catalyst | RODRIGUEZ GEORGE | 2006-11-23 | — | — | US | claimed |
| EP-1704171-A2 | HYDROPHOBIZATION AND SILICA FOR SUPPORTED CATALYST | ExxonMobil Chemical Patents Inc. (US) | 2006-09-27 | — | — | EP | claimed |
| WO-2005075526-A2 | HYDROPHOBIZATION AND SILICA FOR SUPPORTED CATALYST | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-08-18 | — | — | WO | claimed |
| US-20050159299-A1 | Hydrophobization and silica for supported catalyst | EXXONMOBIL CHEMICAL PATENTS INC. | 2005-07-21 | — | — | US | claimed |
| EP-3615527-B1 | NEW AZAQUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-03-06 | — | — | EP | disclosed |
| CN-110770227-B | Novel azaquinoline derivatives | 拜耳动物保健有限责任公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| CN-110536892-B | Novel bicyclic pyrazole derivatives | 拜耳动物保健有限责任公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-4132911-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | Bayer Animal Health GmbH (DE) | 2023-02-15 | — | — | EP | disclosed |
| WO-2018197401-A1 | NEW BICYCLIC PYRAZOLE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018087036-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
| US-7217676-B2 | Hydrophobization and silica for supported catalyst | EXXON MOBIL CHEMICAL PATENTS INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20060264320-A1 | Hydrophobization and silica for supported catalyst | RODRIGUEZ GEORGE | 2006-11-23 | — | — | US | disclosed |
| EP-1704171-A2 | HYDROPHOBIZATION AND SILICA FOR SUPPORTED CATALYST | ExxonMobil Chemical Patents Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005075526-A2 | HYDROPHOBIZATION AND SILICA FOR SUPPORTED CATALYST | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050159299-A1 | Hydrophobization and silica for supported catalyst | EXXONMOBIL CHEMICAL PATENTS INC. | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | H1-5, H1-10, H1-0 | PDGFRB 3299/4885PDGFRA 2115/4885DBH 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.